| US 7,585,976 B2 | ||
| Hemiasterlin derivatives and uses thereof | ||
| Silvio A. Campagna, Candia, N.H. (US); Francis G. Fang, Andover, Mass. (US); James J. Kowalczyk, Andover, Mass. (US); Shawn Schiller, Haverhill, Mass. (US); Boris M. Seletsky, Andover, Mass. (US); Mark Spyvee, Hampstead, N.H. (US); and Hu Yang, Andover, Mass. (US) | ||
| Assigned to Eisai Co., Ltd., Tokyo (Japan) | ||
| Filed on Jan. 26, 2006, as Appl. No. 11/340,256. | ||
| Application 11/340256 is a division of application No. 10/667864, filed on Sep. 22, 2003, granted, now 7,064,211. | ||
| Application 10/667864 is a continuation in part of application No. PCT/US03/08888, filed on Mar. 21, 2003. | ||
| Claims priority of provisional application 60/366592, filed on Mar. 22, 2002. | ||
| Prior Publication US 2006/0154872 A1, Jul. 13, 2006 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. C07D 215/14 (2006.01) | ||
| U.S. Cl. 546—179 | 10 Claims |
1. An intermediate having the structure:
 wherein g is 2;
L is CRL1RL2, wherein each occurrence of RL1 and RL2 is hydrogen;
each occurrence of RG1, RM1 and RM2 is hydrogen or an aliphatic moiety;
provided that any two adjacent RL1, RL2, RG1, RM1 or RM2 groups, taken together, form a substituted or unsubstituted alicyclic moiety containing 3-6 atoms or an aryl moiety;
R2 is hydrogen or an aliphatic moiety; and
R6 is hydrogen or an aliphatic moiety.
|